Enlivex Therapeutics Ltd. (ENLV)

0.8923

-0.0541

(-5.72%)

As of 2:28:43 PM EDT. Market Open.

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Name	Title	Pay	Exercised	Year Born
Mr. Shai Novik M.B.A.	Executive Chairman	528k	--	1966
Dr. Oren Hershkovitz Ph.D.	Chief Executive Officer	273.6k	--	1977
Prof. Dror Mevorach M.D.	Founder & Scientific Advisor	180k	--	1956
Ms. Shachar Shlosberger CPA	Chief Financial Officer	126k	--	1977
Dr. Veronique Amor-Baroukh	Senior Director of Operations	--	--	--
Ms. Sigal Arad	Director of Human Resources	--	--	--

14 Einstein Street

Ness Ziona, 7403618

Israel

972 2 670 8072 https://www.enlivex.com

Sector:: Healthcare
Industry:

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events Information Not Available

March 31, 2025 at 12:00 AM UTC